Print this page
-
Molecular Monitoring with Circulating Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma
Protocol: 011908Principal Investigator:
- Kevin David M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Managed Access Program (MAP) to Provide Access to CTL019, for Acute Lymphoblastic Leukemia (ALL) or Large B-cell Lymphoma Patients without of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release.
Protocol: 021908Principal Investigator:
- Dennis Cooper M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma
Lymphoid Leukemia -
NCI/CTEP #9681: A Phase I Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
Protocol: 051512Principal Investigator:
- Biren Saraiya M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Kidney
Prostate
Urinary Bladder
Other Urinary -
E4412: A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
Protocol: 011505Principal Investigator:
- Kevin David M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Hodgkin's Lymphoma -
A Prospective Trial of Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for the Treatment of Metastatic Lung Cancer: SBRT Sensitization of the Programmed Death-1 (PD-1) Effect
Protocol: 031907Principal Investigator:
- David D'Ambrosio (Community Medical Center)
Applicable Disease Sites: Lung -
Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma.
Protocol: 011818Principal Investigator:
- Dennis Cooper M.D (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Multiple Myeloma
